Fully human monoclonal antibody developed to disrupt the signal
LARTRUVO disrupts PDGFR-α pathway signaling and can inhibit tumor growth.
As demonstrated in nonclinical studies, LARTRUVO binds PDGFR‑α, preventing receptor activation. LARTRUVO exhibits in vitro and in vivo anti-tumor activity against selected sarcoma cell lines and disrupts the PDGFR-α signaling pathway in in vivo tumor implant models.
PDGFR-α=platelet-derived growth factor receptor alpha.